Dicerna Presents New Nonclinical Research Highlighting the Application of its RNAi Technology in Extrahepatic Tissues at TIDES Europe 2020
Nov 10, 2020
The presentation, titled, “Progress on a Pipeline of Extrahepatic RNAi Therapeutics,” includes nonclinical data demonstrating messenger RNA (mRNA) knockdown activity in multiple extrahepatic tissues using therapeutic nucleic acid modalities leveraging Dicerna’s proprietary RNAi technology. The presentation will be available from the conference website as part of the Oligonucleotide Discovery, Preclinical and Clinical track of TIDES Europe and will be viewable online for 30 days following the conference. The slides from the presentation will also be made available on the Events & Presentations page of Dicerna’s corporate website.
“Since introducing our proprietary GalXC™ technology four years ago, we have successfully advanced multiple candidates into clinical studies for genetically defined rare and prevalent diseases affecting the liver,” said
The TIDES Europe conference will also feature an on-demand presentation and a live, moderated panel discussion focusing on Dicerna’s RNAi discovery and development collaboration with Novo Nordisk A/S. Dr. Brown and
Cautionary Note on Forward-Looking Statements
This press release includes forward-looking statements pertaining to the Company’s planned attendance and presentation at a virtual scientific conference, which will include discussion of the Company’s progress with the development of extrahepatic RNAi therapeutics, our ability to create and develop investigational therapies, the potential of other indications that may be targeted by RNAi, as well as our business and operations, including the discovery, development and commercialization of our product candidates and technology platform, and the therapeutic potential thereof, the success of our collaboration with partners and any potential future collaborations. Such forward-looking statements are subject to risks and uncertainties that could cause actual results to differ materially from those expressed or implied in such statements. Applicable risks and uncertainties include those risks identified under the heading “Risk Factors” included in our most recent Form 10-Q filing and in other future filings with the
GalXC™ is a trademark of